FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200058814> ?p ?o ?g. }

• W3200058814 abstract "Abstract Background Restenosis after angioplasty is a major challenge for the treatment of coronary artery diseases. Facilitation of vascular smooth muscle cell (VSMC) apoptosis may be an attractive approach to decrease the incidence of restenosis. We synthesized a 16-amino acid mitofusin-2 (Mfn-2) gene related peptide (MRSP) based on the sequence of the p21 ras signature motif, the smallest functional sequence of the Mfn-2 gene with proapoptotic properties in VSMC. We investigated whether MRSP enhanced apoptotic activities to inhibit VSMC accumulation and neointimal hyperplasia in rats with carotid balloon injury. Methods VSMCs were treated with different concentrations of MRSP, the PI3K agonist 740 Y-P and the inhibitor LY294002. Cell apoptosis and related pathway molecules were assessed. MRSP was also given to rats with carotid artery balloon injury. Neointimal hyperplasia and cell apoptotic pathways were detected. Results In vitro experiments revealed that MRSP treatment significantly increased VSMC apoptosis and induced increases in procaspase-9 cleavage, caspase-3 activation, cytochrome c release from mitochondria to the cytoplasm and the Bax/Bcl-2 ratio but not caspase-8 expression, indicating that the mitochondrial apoptotic cascade was activated by MRSP, which might be attributed to suppression of the PI3K/Akt signaling pathway. We further found that the PI3K agonist 740 Y-P prevented and that the inhibitor LY294002 strengthened the proapoptotic effects of MRSP. MRSP strongly inhibited neointimal hyperplasia and VSMC accumulation, but increased VSMC apoptosis in the vascular wall after balloon injury. Moreover, MRSP substantially enhanced Bax and cleaved caspase-3 expression and decreased Bcl-2 levels in intima, accompanied by decreased levels of phosphorylated Akt and PI3K in vivo. Conclusions Taken together, the present study showed that MRSP treatment results in a strong proapoptotic effect by activating the mitochondrial apoptotic cascade through suppression of the PI3K/Akt pathway." @default.
• W3200058814 created "2021-09-27" @default.
• W3200058814 creator A5018166354 @default.
• W3200058814 creator A5035441171 @default.
• W3200058814 creator A5040856831 @default.
• W3200058814 creator A5041465873 @default.
• W3200058814 creator A5049039743 @default.
• W3200058814 creator A5053451644 @default.
• W3200058814 creator A5056641419 @default.
• W3200058814 creator A5083238725 @default.
• W3200058814 creator A5085629666 @default.
• W3200058814 date "2021-09-19" @default.
• W3200058814 modified "2023-10-17" @default.
• W3200058814 title "A new Mfn-2 related synthetic peptide promotes vascular smooth muscle cell apoptosis via regulating the mitochondrial apoptotic pathway by inhibiting Akt signaling" @default.
• W3200058814 cites W1982999386 @default.
• W3200058814 cites W1996801852 @default.
• W3200058814 cites W2003121859 @default.
• W3200058814 cites W2007185928 @default.
• W3200058814 cites W2008757142 @default.
• W3200058814 cites W2031398866 @default.
• W3200058814 cites W2033718728 @default.
• W3200058814 cites W2052910631 @default.
• W3200058814 cites W2058938316 @default.
• W3200058814 cites W2060149475 @default.
• W3200058814 cites W2074305443 @default.
• W3200058814 cites W2080155177 @default.
• W3200058814 cites W2091220982 @default.
• W3200058814 cites W2104828119 @default.
• W3200058814 cites W2109220337 @default.
• W3200058814 cites W2135458368 @default.
• W3200058814 cites W2140723469 @default.
• W3200058814 cites W2146917818 @default.
• W3200058814 cites W2171699025 @default.
• W3200058814 cites W2327005991 @default.
• W3200058814 cites W2338391796 @default.
• W3200058814 cites W2528962984 @default.
• W3200058814 cites W2534325816 @default.
• W3200058814 cites W2537719889 @default.
• W3200058814 cites W2587363040 @default.
• W3200058814 cites W2609730037 @default.
• W3200058814 cites W2746982895 @default.
• W3200058814 cites W2752862273 @default.
• W3200058814 cites W2766411031 @default.
• W3200058814 cites W2915804162 @default.
• W3200058814 cites W2924466413 @default.
• W3200058814 doi "https://doi.org/10.1186/s12967-021-03064-1" @default.
• W3200058814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8451139" @default.
• W3200058814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34538249" @default.
• W3200058814 hasPublicationYear "2021" @default.
• W3200058814 type Work @default.
• W3200058814 sameAs 3200058814 @default.
• W3200058814 citedByCount "4" @default.
• W3200058814 countsByYear W32000588142022 @default.
• W3200058814 countsByYear W32000588142023 @default.
• W3200058814 crossrefType "journal-article" @default.
• W3200058814 hasAuthorship W3200058814A5018166354 @default.
• W3200058814 hasAuthorship W3200058814A5035441171 @default.
• W3200058814 hasAuthorship W3200058814A5040856831 @default.
• W3200058814 hasAuthorship W3200058814A5041465873 @default.
• W3200058814 hasAuthorship W3200058814A5049039743 @default.
• W3200058814 hasAuthorship W3200058814A5053451644 @default.
• W3200058814 hasAuthorship W3200058814A5056641419 @default.
• W3200058814 hasAuthorship W3200058814A5083238725 @default.
• W3200058814 hasAuthorship W3200058814A5085629666 @default.
• W3200058814 hasBestOaLocation W32000588141 @default.
• W3200058814 hasConcept C126322002 @default.
• W3200058814 hasConcept C134018914 @default.
• W3200058814 hasConcept C185592680 @default.
• W3200058814 hasConcept C190283241 @default.
• W3200058814 hasConcept C2776912716 @default.
• W3200058814 hasConcept C2778095995 @default.
• W3200058814 hasConcept C2778283817 @default.
• W3200058814 hasConcept C2778583881 @default.
• W3200058814 hasConcept C2779395532 @default.
• W3200058814 hasConcept C29311851 @default.
• W3200058814 hasConcept C2992686903 @default.
• W3200058814 hasConcept C502942594 @default.
• W3200058814 hasConcept C55493867 @default.
• W3200058814 hasConcept C71924100 @default.
• W3200058814 hasConcept C86554907 @default.
• W3200058814 hasConcept C86803240 @default.
• W3200058814 hasConcept C95444343 @default.
• W3200058814 hasConceptScore W3200058814C126322002 @default.
• W3200058814 hasConceptScore W3200058814C134018914 @default.
• W3200058814 hasConceptScore W3200058814C185592680 @default.
• W3200058814 hasConceptScore W3200058814C190283241 @default.
• W3200058814 hasConceptScore W3200058814C2776912716 @default.
• W3200058814 hasConceptScore W3200058814C2778095995 @default.
• W3200058814 hasConceptScore W3200058814C2778283817 @default.
• W3200058814 hasConceptScore W3200058814C2778583881 @default.
• W3200058814 hasConceptScore W3200058814C2779395532 @default.
• W3200058814 hasConceptScore W3200058814C29311851 @default.
• W3200058814 hasConceptScore W3200058814C2992686903 @default.
• W3200058814 hasConceptScore W3200058814C502942594 @default.
• W3200058814 hasConceptScore W3200058814C55493867 @default.
• W3200058814 hasConceptScore W3200058814C71924100 @default.
• W3200058814 hasConceptScore W3200058814C86554907 @default.
• W3200058814 hasConceptScore W3200058814C86803240 @default.
• W3200058814 hasConceptScore W3200058814C95444343 @default.
• W3200058814 hasFunder F4320321001 @default.

• next